We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Federal investigators have been looking into possible price fixing at top generic drugmakers for years, and on Friday, a top Department of Justice official signaled what his agency might do next.